verticillins: 3 antibiotics isolated from imperfect fungus Verticillium: verticillin A, verticillin B (mono-3-hydroxymethyl analog of verticillin A), & verticillin C (differs from verticillin B in that 1 of dioxopiperazine rings has a trisulfide rather than a disulfide bridge; active against gram-positive bacteria & mycobacteria but not against gram-negative bacteria & fungi; RN given refers to cpd with unknown MF; structure (verticillins A & B)) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3084126 |
| CHEMBL ID | 2172426 |
| SCHEMBL ID | 20796090 |
| MeSH ID | M0054530 |
| Synonym |
|---|
| 12795-76-5 |
| unii-bdq3m208xa |
| bdq3m208xa , |
| verticillin |
| verticillins |
| 11,11'-dideoxyverticillin a |
| chembl2172426 , |
| bdbm50396026 |
| (10b,10'b(11h,11'h)-bi-3,11a-epidithio-11ah-pyrazino(1',2':1,5)pyrrolo(2,3-b)indole)-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-2,2',3,3'-tetramethyl-, (3s,3's,5ar,5'ar,10br,10'br,11as,11'as)- |
| (3s,3's,5ar,5'ar,10br,10'br,11as,11'as)-2,2',3,3',5a,5'a,6,6'-octahydro-2,2',3,3'-tetramethyl(10b,10'b(11h,11'h)-bi-3,11a-epidithio-11ah-pyrazino(1',2':1,5)pyrrolo(2,3-b)indole)-1,1',4,4'-tetrone |
| L03PG2D98P |
| zh-4b |
| (+)-11,11'-dideoxyverticillin a |
| 11,11'-dideoxyverticillin a, (+)- |
| (1s,3r,11r,14s)-3-[(1s,3r,11r,14s)-14,18-dimethyl-13,17-dioxo-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-trien-3-yl]-14,18-dimethyl-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13, |
| SCHEMBL20796090 |
Verticillins are a group of epipolythiodioxopiperazine alkaloids that have displayed potent cytotoxicity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Verticillins are a group of epipolythiodioxopiperazine alkaloids that have displayed potent cytotoxicity. " | ( Media studies to enhance the production of verticillins facilitated by in situ chemical analysis. Amrine, CSM; Darveaux, BA; Oberlies, NH; Pearce, CJ; Raja, HA, 2018) | 2.19 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The assay was applied to determine plasma drug concentration in a mouse pharmacokinetic study." | ( Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. Kolli, S; Oberlies, NH; Pearce, CJ; Phelps, MA; Wang, H; Wang, J; Zhu, X, 2017) | 0.46 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The current study aims to investigate the pharmacokinetics and bioavailability of verticillin A in mice to provide guidance for further efficacy assessment in mouse models." | ( Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry. Kolli, S; Oberlies, NH; Pearce, CJ; Phelps, MA; Wang, H; Wang, J; Zhu, X, 2017) | 0.46 |
| " Tolerability studies to optimize verticillin A formulation for in vivo delivery were performed and compared to a semi-synthetic succinate version of verticillin A to monitor bioavailability in athymic nude females." | ( Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models. Bazioli, JM; Burdette, JE; Coss, CC; Fuchs, JR; Hill, KL; Kaweesa, EN; Kulp, SK; Lantvit, DD; Oberlies, NH; Pearce, CJ; Phelps, MA; Pierre, HC, 2023) | 1.26 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Moreover, we observed that the loss of cell viability and cell growth inhibition induced by C42 were both time- and dosage dependent." | ( [11'-Deoxyverticillin A induces caspase-dependent cell apoptosis in PC3M cells]. Ni, Y; Shi, G; Shi, Y; Yang, H; Zhang, Y, 2012) | 0.38 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Histone-lysine N-methyltransferase SUV39H1 | Homo sapiens (human) | IC50 (µMol) | 0.5300 | 0.0660 | 0.5140 | 1.2000 | AID700488 |
| Histone-lysine N-methyltransferase EHMT2 | Homo sapiens (human) | IC50 (µMol) | 0.6300 | 0.0025 | 1.1480 | 9.2000 | AID700489 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID700489 | Inhibition of G9a | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Oncoepigenomics: making histone lysine methylation count. |
| AID700488 | Inhibition of SUV39H1 | 2012 | European journal of medicinal chemistry, Oct, Volume: 56 | Oncoepigenomics: making histone lysine methylation count. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.94) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (8.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 23 (92.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||